FHTX

Foghorn Therapeutics Inc.
CAPPED RATING

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Foghorn Therapeutics Inc. (FHTX) is rated D (1.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Revisions (F).

Quantitative Factor Evaluation • Updated

Overall Rating
1.3 / 5.0
D
Value
B
Factor Score 3.3 / 5.0
Growth
F
Factor Score 0.6 / 5.0
Profitability
D+
Factor Score 1.8 / 5.0
Momentum
D-
Factor Score 0.7 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 23.2
EV / EBITDA 1.2
Rev Growth YoY N/M
Gross Margin 30.7%
Price Return 3M -67.8%
Price Return 12M -52.7%
Catalyst Signal 0.00
Market Cap $125.3M
TTM Revenue $112.1M
Price / Sales 1.1
ROE N/A

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 B (3.3) F (0.6) D+ (1.8) D- (0.7) F (0.0) D (1.3)
2026-11-05 B- (3.0) C- (2.1) D (1.5) D- (0.8) F (0.0) D (1.5)
2026-10-29 B- (3.0) C (2.2) D+ (1.5) D (1.5) F (0.0) D+ (1.6)
2026-10-22 B (3.3) C (2.2) D+ (1.5) D+ (1.6) F (0.0) D+ (1.7)
2026-10-15 B (3.4) C (2.2) D+ (1.5) D+ (1.6) F (0.0) D+ (1.7)
Page 1 of 6